Ignyta files IND application with FDA for tumour drug RXDX-101

Ignyta has filed an investigational new drug application (IND) with the US Food and Drug Administration (FDA) for its RXDX-101, an oral tyrosine kinase inhibitor targeting solid tumour indications.

Source: Pharmaceutical Technology - March 3, 2014 Category: Pharmaceuticals Source Type: news